Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Larrey

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 9, 2022
A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?Edouard Larrey, Filomena Conti, Manon Allaire
Liver International : Official Journal of the International Association for the Study of the Liver|March 10, 2020
ALBI-based BCLC nomogram: A new or an additional prognostic tool?Xavier Adhoute, Edouard Larrey, Guillaume Pénaranda, et al.
Clinics and Research in Hepatology and Gastroenterology|August 13, 2021
Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !Bertille Campion, Edouard Larrey, Mathilde Wagner, et al.
Clinics and Research in Hepatology and Gastroenterology|November 6, 2021
"De novo" cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed!Pauline Bourdeleau, Edouard Larrey, Manon Allaire, et al.
Clinics and Research in Hepatology and Gastroenterology|August 17, 2021
TIPS for patients with early HCC: A bridge to liver transplantationEdouard Larrey, Philippe Cluzel, Marika Rudler, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2023
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinomaManon Allaire, Bertille Campion, Alix Demory, et al.
Clinics and Research in Hepatology and Gastroenterology|January 8, 2024
Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survivalAmel Mejait, Charles Roux, Marine Soret, et al.
Clinics and Research in Hepatology and Gastroenterology|September 4, 2023
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCCSayma Chaibi, Edouard Larrey, Jean Pierre Couty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2022
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCCEdouard Larrey, Bertille Campion, Manon Evain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 28, 2024
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-BevacizumabPhilippe Sultanik, Claudia Campani, Edouard Larrey, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 9, 2022
A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?Edouard Larrey, Filomena Conti, Manon Allaire
Liver International : Official Journal of the International Association for the Study of the Liver|March 10, 2020
ALBI-based BCLC nomogram: A new or an additional prognostic tool?Xavier Adhoute, Edouard Larrey, Guillaume Pénaranda, et al.
Clinics and Research in Hepatology and Gastroenterology|August 13, 2021
Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !Bertille Campion, Edouard Larrey, Mathilde Wagner, et al.
Clinics and Research in Hepatology and Gastroenterology|November 6, 2021
"De novo" cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed!Pauline Bourdeleau, Edouard Larrey, Manon Allaire, et al.
Clinics and Research in Hepatology and Gastroenterology|August 17, 2021
TIPS for patients with early HCC: A bridge to liver transplantationEdouard Larrey, Philippe Cluzel, Marika Rudler, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2023
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinomaManon Allaire, Bertille Campion, Alix Demory, et al.
Clinics and Research in Hepatology and Gastroenterology|January 8, 2024
Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survivalAmel Mejait, Charles Roux, Marine Soret, et al.
Clinics and Research in Hepatology and Gastroenterology|September 4, 2023
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCCSayma Chaibi, Edouard Larrey, Jean Pierre Couty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2022
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCCEdouard Larrey, Bertille Campion, Manon Evain, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 28, 2024
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-BevacizumabPhilippe Sultanik, Claudia Campani, Edouard Larrey, et al.
Pageof 2